Global Pulmonary Drug Delivery Systems

Pulmonary Drug Delivery Systems Comprehensive Study by Type (Metered Dose Inhalers (Manually-Actuated Pressurized Inhaler, Breath-Actuated Pressurized Inhaler), Dry Powder Inhalers (Single-Dose Inhalers, Multi-Dose Inhalers), Nebulizers (Mesh, Pneumatic, Ultrasonic), Accessories), Application (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Other), End User (Hospitals & Clinics, Homecare) Players and Region - Global Market Outlook to 2030

Pulmonary Drug Delivery Systems Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 4.6%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Pulmonary Drug Delivery Systems
The Pulmonary Drug Delivery System market is expected to mark significant growth over the forecasted period owing to the increasing prevalence of respiratory diseases, availability of advanced technology, and continuous launch of new products. Pulmonary drug delivery routes present several advantages compared to conventional drug administration, such as fewer systemic side effects than oral or parenteral administration. The systems most commonly used for respiratory delivery, including nebulizers, metered-dose inhalers, and dry powder inhalers, can all be adapted for use with protein/peptide drugs.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR4.6%


Leading key players are focusing on strategic partnerships to improve their products and services. Companies are focusing on increasing their client base to strengthen market position and to enhance product & service offerings. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Pulmonary Drug Delivery Systems market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

GlaxoSmithKline plc. (United Kingdom), Koninklijke Philips N.V. (Netherlands), Boehringer Ingelheim International GmbH (Germany), 3M (United States), Teva Pharmaceutical Industries Ltd. (Israel), Aerogen Ltd.(Ireland), Hovione (Portugal), Hantel Technologies (United States), H&T Presspart Manufacturing Ltd. (United Kingdom), Philips Respironics (United States), AstraZeneca plc. (United Kingdom) and Novartis AG (Switzerland) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Omron Healthcare (United States) and PARI Respiratory Equipment, Inc (United States).

Segmentation Overview
AMA Research has segmented the market of Global Pulmonary Drug Delivery Systems market by Type (Metered Dose Inhalers (Manually-Actuated Pressurized Inhaler, Breath-Actuated Pressurized Inhaler), Dry Powder Inhalers (Single-Dose Inhalers, Multi-Dose Inhalers), Nebulizers (Mesh, Pneumatic, Ultrasonic) and Accessories), Application (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other) and Region.



On the basis of geography, the market of Pulmonary Drug Delivery Systems has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End User, the sub-segment i.e. Hospitals & Clinics will boost the Pulmonary Drug Delivery Systems market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Technological Advancements in Pulmonary Drug Delivery Systems

Market Growth Drivers:
Increasing Incidence of Respiratory Diseases and Rising Preference for Pulmonary Drug Delivery as an Alternate Route of Drug Delivery

Challenges:
Regulatory Issues related to Approval of Pulmonary Drug Delivery Systems

Restraints:
High Pricing Pressures

Opportunities:
Increase in Research and Developments Activities and Growth Opportunities in Emerging Markets

Market Leaders and their expansionary development strategies
On May 3, 2023, Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, and H&T Presspart, leading manufacturer of drug delivery devices, has entered in a strategic partnership to advance the development of Presspart's Sunriser Capsule-based Dry Powder Inhaler platform. The demand for inhalable drugs that require higher drug loads and the delivery of cohesive materials has increased, making it necessary to develop more efficient solutions. To meet this demand, the two companies will work together to develop the Sunriser Dry Powder Inhaler. This innovative and best-in-class capsule-based platform is flexible enough to address both the challenges of classic carrier-based and spray-dried engineered formulations.
On April 3, 2023, PureIMS, a clinical stage pharmaceutical company, announced it has secured a new investment round by Boost-UP Foundation, a private independent foundations. With the current investments the company also pursues opportunities to further enthuse pharma/biotech companies for early-clinical endeavors looking for innovative pulmonary delivery options to develop small and large molecules for local and systemic indications.
In June 2020, researchers from the University of Szeged, Hungary, reported the development of a carrier-based DPI system, which is an interactive physical blend of a surface-modified carrier and a spray-dried drug with a suitable shape and size for the pulmonary application.

Key Target Audience
Manufacturers of Pulmonary Drug Delivery Systems, Distributors & Suppliers of Pulmonary Drug Delivery Systems, Raw Material Suppliers, Research Institutes and Academic Centers, Government Associations, Market Research and Consulting Firms, Venture Capitalists and Investors and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Metered Dose Inhalers (Manually-Actuated Pressurized Inhaler, Breath-Actuated Pressurized Inhaler)
  • Dry Powder Inhalers (Single-Dose Inhalers, Multi-Dose Inhalers)
  • Nebulizers (Mesh, Pneumatic, Ultrasonic)
  • Accessories
By Application
  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Cystic Fibrosis
  • Other
By End User
  • Hospitals & Clinics
  • Homecare

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Incidence of Respiratory Diseases
      • 3.2.2. Rising Preference for Pulmonary Drug Delivery as an Alternate Route of Drug Delivery
    • 3.3. Market Challenges
      • 3.3.1. Regulatory Issues related to Approval of Pulmonary Drug Delivery Systems
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements in Pulmonary Drug Delivery Systems
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Pulmonary Drug Delivery Systems, by Type, Application, End User and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Pulmonary Drug Delivery Systems (Value)
      • 5.2.1. Global Pulmonary Drug Delivery Systems by: Type (Value)
        • 5.2.1.1. Metered Dose Inhalers (Manually-Actuated Pressurized Inhaler, Breath-Actuated Pressurized Inhaler)
        • 5.2.1.2. Dry Powder Inhalers (Single-Dose Inhalers, Multi-Dose Inhalers)
        • 5.2.1.3. Nebulizers (Mesh, Pneumatic, Ultrasonic)
        • 5.2.1.4. Accessories
      • 5.2.2. Global Pulmonary Drug Delivery Systems by: Application (Value)
        • 5.2.2.1. Asthma
        • 5.2.2.2. Chronic Obstructive Pulmonary Disease (COPD)
        • 5.2.2.3. Cystic Fibrosis
        • 5.2.2.4. Other
      • 5.2.3. Global Pulmonary Drug Delivery Systems by: End User (Value)
        • 5.2.3.1. Hospitals & Clinics
        • 5.2.3.2. Homecare
      • 5.2.4. Global Pulmonary Drug Delivery Systems Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Pulmonary Drug Delivery Systems (Price)
      • 5.3.1. Global Pulmonary Drug Delivery Systems by: Type (Price)
  • 6. Pulmonary Drug Delivery Systems: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline plc. (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Koninklijke Philips N.V. (Netherlands)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Boehringer Ingelheim International GmbH (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. 3M (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Aerogen Ltd.(Ireland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Hovione (Portugal)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Hantel Technologies (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. H&T Presspart Manufacturing Ltd. (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Philips Respironics (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. AstraZeneca plc. (United Kingdom)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Novartis AG (Switzerland)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Pulmonary Drug Delivery Systems Sale, by Type, Application, End User and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Pulmonary Drug Delivery Systems (Value)
      • 7.2.1. Global Pulmonary Drug Delivery Systems by: Type (Value)
        • 7.2.1.1. Metered Dose Inhalers (Manually-Actuated Pressurized Inhaler, Breath-Actuated Pressurized Inhaler)
        • 7.2.1.2. Dry Powder Inhalers (Single-Dose Inhalers, Multi-Dose Inhalers)
        • 7.2.1.3. Nebulizers (Mesh, Pneumatic, Ultrasonic)
        • 7.2.1.4. Accessories
      • 7.2.2. Global Pulmonary Drug Delivery Systems by: Application (Value)
        • 7.2.2.1. Asthma
        • 7.2.2.2. Chronic Obstructive Pulmonary Disease (COPD)
        • 7.2.2.3. Cystic Fibrosis
        • 7.2.2.4. Other
      • 7.2.3. Global Pulmonary Drug Delivery Systems by: End User (Value)
        • 7.2.3.1. Hospitals & Clinics
        • 7.2.3.2. Homecare
      • 7.2.4. Global Pulmonary Drug Delivery Systems Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Pulmonary Drug Delivery Systems (Price)
      • 7.3.1. Global Pulmonary Drug Delivery Systems by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Pulmonary Drug Delivery Systems: by Type(USD Million)
  • Table 2. Pulmonary Drug Delivery Systems Metered Dose Inhalers (Manually-Actuated Pressurized Inhaler, Breath-Actuated Pressurized Inhaler) , by Region USD Million (2018-2023)
  • Table 3. Pulmonary Drug Delivery Systems Dry Powder Inhalers (Single-Dose Inhalers, Multi-Dose Inhalers) , by Region USD Million (2018-2023)
  • Table 4. Pulmonary Drug Delivery Systems Nebulizers (Mesh, Pneumatic, Ultrasonic) , by Region USD Million (2018-2023)
  • Table 5. Pulmonary Drug Delivery Systems Accessories , by Region USD Million (2018-2023)
  • Table 6. Pulmonary Drug Delivery Systems: by Application(USD Million)
  • Table 7. Pulmonary Drug Delivery Systems Asthma , by Region USD Million (2018-2023)
  • Table 8. Pulmonary Drug Delivery Systems Chronic Obstructive Pulmonary Disease (COPD) , by Region USD Million (2018-2023)
  • Table 9. Pulmonary Drug Delivery Systems Cystic Fibrosis , by Region USD Million (2018-2023)
  • Table 10. Pulmonary Drug Delivery Systems Other , by Region USD Million (2018-2023)
  • Table 11. Pulmonary Drug Delivery Systems: by End User(USD Million)
  • Table 12. Pulmonary Drug Delivery Systems Hospitals & Clinics , by Region USD Million (2018-2023)
  • Table 13. Pulmonary Drug Delivery Systems Homecare , by Region USD Million (2018-2023)
  • Table 14. South America Pulmonary Drug Delivery Systems, by Country USD Million (2018-2023)
  • Table 15. South America Pulmonary Drug Delivery Systems, by Type USD Million (2018-2023)
  • Table 16. South America Pulmonary Drug Delivery Systems, by Application USD Million (2018-2023)
  • Table 17. South America Pulmonary Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 18. Brazil Pulmonary Drug Delivery Systems, by Type USD Million (2018-2023)
  • Table 19. Brazil Pulmonary Drug Delivery Systems, by Application USD Million (2018-2023)
  • Table 20. Brazil Pulmonary Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 21. Argentina Pulmonary Drug Delivery Systems, by Type USD Million (2018-2023)
  • Table 22. Argentina Pulmonary Drug Delivery Systems, by Application USD Million (2018-2023)
  • Table 23. Argentina Pulmonary Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 24. Rest of South America Pulmonary Drug Delivery Systems, by Type USD Million (2018-2023)
  • Table 25. Rest of South America Pulmonary Drug Delivery Systems, by Application USD Million (2018-2023)
  • Table 26. Rest of South America Pulmonary Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 27. Asia Pacific Pulmonary Drug Delivery Systems, by Country USD Million (2018-2023)
  • Table 28. Asia Pacific Pulmonary Drug Delivery Systems, by Type USD Million (2018-2023)
  • Table 29. Asia Pacific Pulmonary Drug Delivery Systems, by Application USD Million (2018-2023)
  • Table 30. Asia Pacific Pulmonary Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 31. China Pulmonary Drug Delivery Systems, by Type USD Million (2018-2023)
  • Table 32. China Pulmonary Drug Delivery Systems, by Application USD Million (2018-2023)
  • Table 33. China Pulmonary Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 34. Japan Pulmonary Drug Delivery Systems, by Type USD Million (2018-2023)
  • Table 35. Japan Pulmonary Drug Delivery Systems, by Application USD Million (2018-2023)
  • Table 36. Japan Pulmonary Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 37. India Pulmonary Drug Delivery Systems, by Type USD Million (2018-2023)
  • Table 38. India Pulmonary Drug Delivery Systems, by Application USD Million (2018-2023)
  • Table 39. India Pulmonary Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 40. South Korea Pulmonary Drug Delivery Systems, by Type USD Million (2018-2023)
  • Table 41. South Korea Pulmonary Drug Delivery Systems, by Application USD Million (2018-2023)
  • Table 42. South Korea Pulmonary Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 43. Taiwan Pulmonary Drug Delivery Systems, by Type USD Million (2018-2023)
  • Table 44. Taiwan Pulmonary Drug Delivery Systems, by Application USD Million (2018-2023)
  • Table 45. Taiwan Pulmonary Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 46. Australia Pulmonary Drug Delivery Systems, by Type USD Million (2018-2023)
  • Table 47. Australia Pulmonary Drug Delivery Systems, by Application USD Million (2018-2023)
  • Table 48. Australia Pulmonary Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Pulmonary Drug Delivery Systems, by Type USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Pulmonary Drug Delivery Systems, by Application USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Pulmonary Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 52. Europe Pulmonary Drug Delivery Systems, by Country USD Million (2018-2023)
  • Table 53. Europe Pulmonary Drug Delivery Systems, by Type USD Million (2018-2023)
  • Table 54. Europe Pulmonary Drug Delivery Systems, by Application USD Million (2018-2023)
  • Table 55. Europe Pulmonary Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 56. Germany Pulmonary Drug Delivery Systems, by Type USD Million (2018-2023)
  • Table 57. Germany Pulmonary Drug Delivery Systems, by Application USD Million (2018-2023)
  • Table 58. Germany Pulmonary Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 59. France Pulmonary Drug Delivery Systems, by Type USD Million (2018-2023)
  • Table 60. France Pulmonary Drug Delivery Systems, by Application USD Million (2018-2023)
  • Table 61. France Pulmonary Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 62. Italy Pulmonary Drug Delivery Systems, by Type USD Million (2018-2023)
  • Table 63. Italy Pulmonary Drug Delivery Systems, by Application USD Million (2018-2023)
  • Table 64. Italy Pulmonary Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 65. United Kingdom Pulmonary Drug Delivery Systems, by Type USD Million (2018-2023)
  • Table 66. United Kingdom Pulmonary Drug Delivery Systems, by Application USD Million (2018-2023)
  • Table 67. United Kingdom Pulmonary Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 68. Netherlands Pulmonary Drug Delivery Systems, by Type USD Million (2018-2023)
  • Table 69. Netherlands Pulmonary Drug Delivery Systems, by Application USD Million (2018-2023)
  • Table 70. Netherlands Pulmonary Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 71. Rest of Europe Pulmonary Drug Delivery Systems, by Type USD Million (2018-2023)
  • Table 72. Rest of Europe Pulmonary Drug Delivery Systems, by Application USD Million (2018-2023)
  • Table 73. Rest of Europe Pulmonary Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 74. MEA Pulmonary Drug Delivery Systems, by Country USD Million (2018-2023)
  • Table 75. MEA Pulmonary Drug Delivery Systems, by Type USD Million (2018-2023)
  • Table 76. MEA Pulmonary Drug Delivery Systems, by Application USD Million (2018-2023)
  • Table 77. MEA Pulmonary Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 78. Middle East Pulmonary Drug Delivery Systems, by Type USD Million (2018-2023)
  • Table 79. Middle East Pulmonary Drug Delivery Systems, by Application USD Million (2018-2023)
  • Table 80. Middle East Pulmonary Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 81. Africa Pulmonary Drug Delivery Systems, by Type USD Million (2018-2023)
  • Table 82. Africa Pulmonary Drug Delivery Systems, by Application USD Million (2018-2023)
  • Table 83. Africa Pulmonary Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 84. North America Pulmonary Drug Delivery Systems, by Country USD Million (2018-2023)
  • Table 85. North America Pulmonary Drug Delivery Systems, by Type USD Million (2018-2023)
  • Table 86. North America Pulmonary Drug Delivery Systems, by Application USD Million (2018-2023)
  • Table 87. North America Pulmonary Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 88. United States Pulmonary Drug Delivery Systems, by Type USD Million (2018-2023)
  • Table 89. United States Pulmonary Drug Delivery Systems, by Application USD Million (2018-2023)
  • Table 90. United States Pulmonary Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 91. Canada Pulmonary Drug Delivery Systems, by Type USD Million (2018-2023)
  • Table 92. Canada Pulmonary Drug Delivery Systems, by Application USD Million (2018-2023)
  • Table 93. Canada Pulmonary Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 94. Mexico Pulmonary Drug Delivery Systems, by Type USD Million (2018-2023)
  • Table 95. Mexico Pulmonary Drug Delivery Systems, by Application USD Million (2018-2023)
  • Table 96. Mexico Pulmonary Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 97. Pulmonary Drug Delivery Systems: by Type(USD/Units)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Pulmonary Drug Delivery Systems: by Type(USD Million)
  • Table 111. Pulmonary Drug Delivery Systems Metered Dose Inhalers (Manually-Actuated Pressurized Inhaler, Breath-Actuated Pressurized Inhaler) , by Region USD Million (2025-2030)
  • Table 112. Pulmonary Drug Delivery Systems Dry Powder Inhalers (Single-Dose Inhalers, Multi-Dose Inhalers) , by Region USD Million (2025-2030)
  • Table 113. Pulmonary Drug Delivery Systems Nebulizers (Mesh, Pneumatic, Ultrasonic) , by Region USD Million (2025-2030)
  • Table 114. Pulmonary Drug Delivery Systems Accessories , by Region USD Million (2025-2030)
  • Table 115. Pulmonary Drug Delivery Systems: by Application(USD Million)
  • Table 116. Pulmonary Drug Delivery Systems Asthma , by Region USD Million (2025-2030)
  • Table 117. Pulmonary Drug Delivery Systems Chronic Obstructive Pulmonary Disease (COPD) , by Region USD Million (2025-2030)
  • Table 118. Pulmonary Drug Delivery Systems Cystic Fibrosis , by Region USD Million (2025-2030)
  • Table 119. Pulmonary Drug Delivery Systems Other , by Region USD Million (2025-2030)
  • Table 120. Pulmonary Drug Delivery Systems: by End User(USD Million)
  • Table 121. Pulmonary Drug Delivery Systems Hospitals & Clinics , by Region USD Million (2025-2030)
  • Table 122. Pulmonary Drug Delivery Systems Homecare , by Region USD Million (2025-2030)
  • Table 123. South America Pulmonary Drug Delivery Systems, by Country USD Million (2025-2030)
  • Table 124. South America Pulmonary Drug Delivery Systems, by Type USD Million (2025-2030)
  • Table 125. South America Pulmonary Drug Delivery Systems, by Application USD Million (2025-2030)
  • Table 126. South America Pulmonary Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 127. Brazil Pulmonary Drug Delivery Systems, by Type USD Million (2025-2030)
  • Table 128. Brazil Pulmonary Drug Delivery Systems, by Application USD Million (2025-2030)
  • Table 129. Brazil Pulmonary Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 130. Argentina Pulmonary Drug Delivery Systems, by Type USD Million (2025-2030)
  • Table 131. Argentina Pulmonary Drug Delivery Systems, by Application USD Million (2025-2030)
  • Table 132. Argentina Pulmonary Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 133. Rest of South America Pulmonary Drug Delivery Systems, by Type USD Million (2025-2030)
  • Table 134. Rest of South America Pulmonary Drug Delivery Systems, by Application USD Million (2025-2030)
  • Table 135. Rest of South America Pulmonary Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 136. Asia Pacific Pulmonary Drug Delivery Systems, by Country USD Million (2025-2030)
  • Table 137. Asia Pacific Pulmonary Drug Delivery Systems, by Type USD Million (2025-2030)
  • Table 138. Asia Pacific Pulmonary Drug Delivery Systems, by Application USD Million (2025-2030)
  • Table 139. Asia Pacific Pulmonary Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 140. China Pulmonary Drug Delivery Systems, by Type USD Million (2025-2030)
  • Table 141. China Pulmonary Drug Delivery Systems, by Application USD Million (2025-2030)
  • Table 142. China Pulmonary Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 143. Japan Pulmonary Drug Delivery Systems, by Type USD Million (2025-2030)
  • Table 144. Japan Pulmonary Drug Delivery Systems, by Application USD Million (2025-2030)
  • Table 145. Japan Pulmonary Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 146. India Pulmonary Drug Delivery Systems, by Type USD Million (2025-2030)
  • Table 147. India Pulmonary Drug Delivery Systems, by Application USD Million (2025-2030)
  • Table 148. India Pulmonary Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 149. South Korea Pulmonary Drug Delivery Systems, by Type USD Million (2025-2030)
  • Table 150. South Korea Pulmonary Drug Delivery Systems, by Application USD Million (2025-2030)
  • Table 151. South Korea Pulmonary Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 152. Taiwan Pulmonary Drug Delivery Systems, by Type USD Million (2025-2030)
  • Table 153. Taiwan Pulmonary Drug Delivery Systems, by Application USD Million (2025-2030)
  • Table 154. Taiwan Pulmonary Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 155. Australia Pulmonary Drug Delivery Systems, by Type USD Million (2025-2030)
  • Table 156. Australia Pulmonary Drug Delivery Systems, by Application USD Million (2025-2030)
  • Table 157. Australia Pulmonary Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 158. Rest of Asia-Pacific Pulmonary Drug Delivery Systems, by Type USD Million (2025-2030)
  • Table 159. Rest of Asia-Pacific Pulmonary Drug Delivery Systems, by Application USD Million (2025-2030)
  • Table 160. Rest of Asia-Pacific Pulmonary Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 161. Europe Pulmonary Drug Delivery Systems, by Country USD Million (2025-2030)
  • Table 162. Europe Pulmonary Drug Delivery Systems, by Type USD Million (2025-2030)
  • Table 163. Europe Pulmonary Drug Delivery Systems, by Application USD Million (2025-2030)
  • Table 164. Europe Pulmonary Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 165. Germany Pulmonary Drug Delivery Systems, by Type USD Million (2025-2030)
  • Table 166. Germany Pulmonary Drug Delivery Systems, by Application USD Million (2025-2030)
  • Table 167. Germany Pulmonary Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 168. France Pulmonary Drug Delivery Systems, by Type USD Million (2025-2030)
  • Table 169. France Pulmonary Drug Delivery Systems, by Application USD Million (2025-2030)
  • Table 170. France Pulmonary Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 171. Italy Pulmonary Drug Delivery Systems, by Type USD Million (2025-2030)
  • Table 172. Italy Pulmonary Drug Delivery Systems, by Application USD Million (2025-2030)
  • Table 173. Italy Pulmonary Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 174. United Kingdom Pulmonary Drug Delivery Systems, by Type USD Million (2025-2030)
  • Table 175. United Kingdom Pulmonary Drug Delivery Systems, by Application USD Million (2025-2030)
  • Table 176. United Kingdom Pulmonary Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 177. Netherlands Pulmonary Drug Delivery Systems, by Type USD Million (2025-2030)
  • Table 178. Netherlands Pulmonary Drug Delivery Systems, by Application USD Million (2025-2030)
  • Table 179. Netherlands Pulmonary Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 180. Rest of Europe Pulmonary Drug Delivery Systems, by Type USD Million (2025-2030)
  • Table 181. Rest of Europe Pulmonary Drug Delivery Systems, by Application USD Million (2025-2030)
  • Table 182. Rest of Europe Pulmonary Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 183. MEA Pulmonary Drug Delivery Systems, by Country USD Million (2025-2030)
  • Table 184. MEA Pulmonary Drug Delivery Systems, by Type USD Million (2025-2030)
  • Table 185. MEA Pulmonary Drug Delivery Systems, by Application USD Million (2025-2030)
  • Table 186. MEA Pulmonary Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 187. Middle East Pulmonary Drug Delivery Systems, by Type USD Million (2025-2030)
  • Table 188. Middle East Pulmonary Drug Delivery Systems, by Application USD Million (2025-2030)
  • Table 189. Middle East Pulmonary Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 190. Africa Pulmonary Drug Delivery Systems, by Type USD Million (2025-2030)
  • Table 191. Africa Pulmonary Drug Delivery Systems, by Application USD Million (2025-2030)
  • Table 192. Africa Pulmonary Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 193. North America Pulmonary Drug Delivery Systems, by Country USD Million (2025-2030)
  • Table 194. North America Pulmonary Drug Delivery Systems, by Type USD Million (2025-2030)
  • Table 195. North America Pulmonary Drug Delivery Systems, by Application USD Million (2025-2030)
  • Table 196. North America Pulmonary Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 197. United States Pulmonary Drug Delivery Systems, by Type USD Million (2025-2030)
  • Table 198. United States Pulmonary Drug Delivery Systems, by Application USD Million (2025-2030)
  • Table 199. United States Pulmonary Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 200. Canada Pulmonary Drug Delivery Systems, by Type USD Million (2025-2030)
  • Table 201. Canada Pulmonary Drug Delivery Systems, by Application USD Million (2025-2030)
  • Table 202. Canada Pulmonary Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 203. Mexico Pulmonary Drug Delivery Systems, by Type USD Million (2025-2030)
  • Table 204. Mexico Pulmonary Drug Delivery Systems, by Application USD Million (2025-2030)
  • Table 205. Mexico Pulmonary Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 206. Pulmonary Drug Delivery Systems: by Type(USD/Units)
  • Table 207. Research Programs/Design for This Report
  • Table 208. Key Data Information from Secondary Sources
  • Table 209. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Pulmonary Drug Delivery Systems: by Type USD Million (2018-2023)
  • Figure 5. Global Pulmonary Drug Delivery Systems: by Application USD Million (2018-2023)
  • Figure 6. Global Pulmonary Drug Delivery Systems: by End User USD Million (2018-2023)
  • Figure 7. South America Pulmonary Drug Delivery Systems Share (%), by Country
  • Figure 8. Asia Pacific Pulmonary Drug Delivery Systems Share (%), by Country
  • Figure 9. Europe Pulmonary Drug Delivery Systems Share (%), by Country
  • Figure 10. MEA Pulmonary Drug Delivery Systems Share (%), by Country
  • Figure 11. North America Pulmonary Drug Delivery Systems Share (%), by Country
  • Figure 12. Global Pulmonary Drug Delivery Systems: by Type USD/Units (2018-2023)
  • Figure 13. Global Pulmonary Drug Delivery Systems share by Players 2023 (%)
  • Figure 14. Global Pulmonary Drug Delivery Systems share by Players (Top 3) 2023(%)
  • Figure 15. Global Pulmonary Drug Delivery Systems share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. GlaxoSmithKline plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. GlaxoSmithKline plc. (United Kingdom) Revenue: by Geography 2023
  • Figure 19. Koninklijke Philips N.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 20. Koninklijke Philips N.V. (Netherlands) Revenue: by Geography 2023
  • Figure 21. Boehringer Ingelheim International GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 22. Boehringer Ingelheim International GmbH (Germany) Revenue: by Geography 2023
  • Figure 23. 3M (United States) Revenue, Net Income and Gross profit
  • Figure 24. 3M (United States) Revenue: by Geography 2023
  • Figure 25. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 26. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2023
  • Figure 27. Aerogen Ltd.(Ireland) Revenue, Net Income and Gross profit
  • Figure 28. Aerogen Ltd.(Ireland) Revenue: by Geography 2023
  • Figure 29. Hovione (Portugal) Revenue, Net Income and Gross profit
  • Figure 30. Hovione (Portugal) Revenue: by Geography 2023
  • Figure 31. Hantel Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 32. Hantel Technologies (United States) Revenue: by Geography 2023
  • Figure 33. H&T Presspart Manufacturing Ltd. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. H&T Presspart Manufacturing Ltd. (United Kingdom) Revenue: by Geography 2023
  • Figure 35. Philips Respironics (United States) Revenue, Net Income and Gross profit
  • Figure 36. Philips Respironics (United States) Revenue: by Geography 2023
  • Figure 37. AstraZeneca plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 38. AstraZeneca plc. (United Kingdom) Revenue: by Geography 2023
  • Figure 39. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 40. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 41. Global Pulmonary Drug Delivery Systems: by Type USD Million (2025-2030)
  • Figure 42. Global Pulmonary Drug Delivery Systems: by Application USD Million (2025-2030)
  • Figure 43. Global Pulmonary Drug Delivery Systems: by End User USD Million (2025-2030)
  • Figure 44. South America Pulmonary Drug Delivery Systems Share (%), by Country
  • Figure 45. Asia Pacific Pulmonary Drug Delivery Systems Share (%), by Country
  • Figure 46. Europe Pulmonary Drug Delivery Systems Share (%), by Country
  • Figure 47. MEA Pulmonary Drug Delivery Systems Share (%), by Country
  • Figure 48. North America Pulmonary Drug Delivery Systems Share (%), by Country
  • Figure 49. Global Pulmonary Drug Delivery Systems: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline plc. (United Kingdom)
  • Koninklijke Philips N.V. (Netherlands)
  • Boehringer Ingelheim International GmbH (Germany)
  • 3M (United States)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Aerogen Ltd.(Ireland)
  • Hovione (Portugal)
  • Hantel Technologies (United States)
  • H&T Presspart Manufacturing Ltd. (United Kingdom)
  • Philips Respironics (United States)
  • AstraZeneca plc. (United Kingdom)
  • Novartis AG (Switzerland)
Additional players considered in the study are as follows:
Omron Healthcare (United States) , PARI Respiratory Equipment, Inc (United States)
Select User Access Type

Key Highlights of Report


Apr 2024 229 Pages 96 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Pulmonary Drug Delivery Systems Quantitative research analysis
Global Pulmonary Drug Delivery Systems Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as GlaxoSmithKline plc. (United Kingdom), Koninklijke Philips N.V. (Netherlands), Boehringer Ingelheim International GmbH (Germany), 3M (United States), Teva Pharmaceutical Industries Ltd. (Israel), Aerogen Ltd.(Ireland), Hovione (Portugal), Hantel Technologies (United States), H&T Presspart Manufacturing Ltd. (United Kingdom), Philips Respironics (United States), AstraZeneca plc. (United Kingdom) and Novartis AG (Switzerland) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Technological Advancements in Pulmonary Drug Delivery Systems" is seen as one of major influencing trends for Pulmonary Drug Delivery Systems Market during projected period 2023-2030.
The Pulmonary Drug Delivery Systems market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Pulmonary Drug Delivery Systems Report?

Have a Query? Click Here

Other Related Reports

Blood Culture Test Comprehensive Study by Type (Consumables (Bacterial Infections, Fungal Infections, Mycobacterial Infections, Blood Culture Media, Assay, Kits, and Reagents, Blood Culture Accessori...
$ 3750
Syphilis Testing Comprehensive Study by Type (Treponemal tests, Non-treponemal tests), Syphilis types (Primary Syphilis, Secondary Syphilis, Others (Latent (hidden) stage, Tertiary (late) stage)), G...
$ 3450
Bioactive Wound Management Comprehensive Study by Type (Moist Wound Care, Antimicrobial Wound Care, Others), Application (Venous Leg Ulcers, Diabetic Foot Ulcers, Pressure Ulcers, Surgical Wounds, Bu...
$ 3750
Ophthalmological Ultrasound Systems Comprehensive Study by Type (A- Scan, B- Scan, Combined Scan, Pachymeter, Ultrasound Bio-microscopy (UBM)), Modality (Portable, Standalone), End User (Hospitals, O...
$ 3350
Clean Room Panels Comprehensive Study by Type (Cleanroom wall Panels, Cleanroom Ceiling Panels, Cleanroom Door Panels, Cleanroom Window Panels, Cleanroom Floor Panels), Application (Food Industry, Op...
$ 3450
Troponin Diagnostic Tests Comprehensive Study by Type (Troponin I ELISA Test, Troponin Rapid test), Sales Channels (Online Sales Channel {Company Website, E-Commerce Platform}, Offline Sales Channels...
$ 3750